Latest Biotech News

Eli Lilly’s investigational co-packaged regimen avutometinib plus defactinib (Avmapki/Fakzynja) won FDA approval for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)...

Eli Lilly is expanding its AI drug discovery footprint through a multibillion-dollar commercialization and development deal with Insilico Medicine. Under terms disclosed by Insilico, Lilly will...

Viridian Therapeutics’ elegrobart (VRDN-003) trial results for active thyroid eye disease drove sharp investor reaction after a pivotal Phase 3 readout showed proptosis improvements but renewed...

Otsuka is moving deeper into neuroplastogen approaches for PTSD via a planned acquisition of Transcend Therapeutics for $1.22 billion. The deal, announced by Otsuka, expands Otsuka’s neuroscience...

Rocket Pharmaceuticals received FDA approval for Kresladi (gene therapy) for leukocyte-adhesion deficiency type 1 (LAD-1), an ultra-rare, potentially fatal inherited immunodeficiency in infants...

ICON is teaming with Advarra to build an integrated, AI-driven site network model aimed at reducing clinical trial startup delays and operational bottlenecks. The collaboration connects ICON’s...

Blackstone closed its largest life sciences private fund on record, raising $6.3 billion for the Blackstone Life Sciences platform (BXLS). The fund is nearly 40% larger than the firm’s prior $4.6...

Roche received U.S. FDA 510(k) clearance for Cobas lab automation units and also gained CE marking for a multiplex blood donor screening assay. The automation modules (Cobas c 703 and Cobas ISE...

Kailera Therapeutics filed for an IPO to fund late-stage development of its obesity portfolio led by ribupatide, a weekly GLP-1/GIP agonist in Phase 3. The filing positions the company to compete...

Researchers reported preclinical progress on engineered immune cell engagers (ICEs) designed to better coordinate activating and inhibitory signals within macrophages for solid tumor clearance. In...

Eli Lilly expanded its AI-driven drug discovery push by signing an agreement with Insilico Medicine to develop and commercialize preclinical oral therapeutics across multiple therapeutic areas....

The FDA approved avutometinib and defactinib as a co-packaged oral combination for adults with KRAS-mutated recurrent LGSOC after prior systemic therapy. The approval is positioned as a rare...

Takeda began workforce reductions in the U.S. tied to a multiyear restructuring plan aimed at more than ¥200 billion ($1.26 billion) in annual cost savings. A WARN notice filed in Massachusetts...

ICON partnered with Advarra to build an integrated, AI-driven site network designed to streamline clinical trial operations. The collaboration combines ICON’s trial services with Advarra’s...

Roche Diagnostics received FDA 510(k) clearance for lab automation modules and secured CE marking for a blood donor screening assay. The company’s Cobas c 703 and Cobas ISE Neo units expand the...

Kailera Therapeutics filed for an IPO as it seeks additional funding to advance a late-stage obesity pipeline, including ribupatide, a weekly GLP-1/GIP agonist. The company plans to list on Nasdaq...

Viridian Therapeutics’ thyroid eye disease (TED) program delivered a phase 3 win, though investors still face questions about commercial positioning. In the REVEAL-1 study of 132 patients,...

Connect Biopharma reported positive phase 3 results for its eczema drug candidate in a 52-week dataset, positioning the company’s therapy as a potential Dupixent challenger. The update centers on...

Alamar Biosciences filed for an IPO, seeking to bring its proteomics and immunoassay platform to public markets. The company plans to list on Nasdaq under ticker “ALMR,” and reported revenue...

Royalty Pharma agreed to co-fund Johnson & Johnson’s $500 million autoimmune antibody program, marking another expansion of Royalty’s royalty-backed development model in immunology. The...